Información de la revista
Original article
Acceso a texto completo
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease
Impacto del tratamiento combinado de dexametasona y tocilizumab sobre parámetros hematológicos en pacientes con enfermedad crónica COVID-19
Haitham M.H. Qutoba,b,
, Ramadan A. Saadb,c, Hamza Balid, Abdulaziz Osailand, Jumana Jaberd, Emad Alzahranid, Jamilah Alyamid, Hani Elsayedb,e, Raed Alserihif,g, Osama A. Shaikhomarh
Autor para correspondencia
a Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabigh, 25732, Saudi Arabia
b Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia
c Physiology Department, Faculty of Medicine, Ainshams University, Cairo, Egypt
d Internal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
e Physics Department, Faculty of Science, Mansoura University, Mansoura, Egypt
f Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
g 3D Bioprinting Unit, Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
h Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
Artículo
This article is available in English
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease
Haitham M.H. Qutob, Ramadan A. Saad, Hamza Bali, Abdulaziz Osailan, Jumana Jaber, Emad Alzahrani, Jamilah Alyami, Hani Elsayed, Raed Alserihi, Osama A. Shaikhomar
10.1016/j.medcli.2022.02.013Med Clin. 2022;159:569-74